{
  "id": "mhgap#risk_safety_a41a2d60",
  "content": "Certainty of evidence: Low\nJustification depressive symptoms and the positive effects of\ny Evidence was extracted from two meta-analyses: antidepressants are considered to be small and not\nHetrick et al., 2021 (26 RCTs) (76); and Zhou et al., clinically significant when compared with placebo\n2020 (71 RCTs) (77). (76).\ny The available very low-certainty evidence shows y SSRI use is associated with an increased risk of\nthat SSRIs (pooled together) and fluoxetine alone suicide and suicide attempts (78). It remains critical\nare related to statistically significant improvements to ensure close monitoring of treatment effects\nin depressive symptoms in adolescents with and suicide-related outcomes (combined suicidal\nmoderate-to-severe depression. However, none ideation and suicide attempt) in adolescents treated\nof the antidepressants were significantly better with SSRIs.\nthan treatment as usual (TAU) in improving\n44\n3. Recommendations\nRemarks EML (13). There must be available and competent\ny The effects of antidepressants might vary between human resources to prescribe medicines safely and\nindividuals, so the adolescents, their carers and monitor any adverse effects.\nclinicians should carefully balance the risk–benefit\nImplementation considerations\nprofile of efficacy, acceptability and suicide risk in\ny Access to psychotherapy, particularly CBT, in line\nyoung people with depression on a case-by-case",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety Certainty of evidence: Low\nJustification depressive symptoms and the positive effects of\ny Evidence was extracted from two meta-analyses: antidepressants are considered to be small and not\nHetrick et al., 2021 (26 RCTs) (76); and Zhou et al., clinically significant when compared with placebo\n2020 (71 RCTs) (77). (76).\ny The available very low-certainty evidence shows y SSRI use is associated with an increased risk of\nthat SSRIs (pooled together) and fluoxetine alone suicide and suicide attempts (78). It remains critical\nare related to statistically significant improvements to ensure close monitoring of treatment effects\nin depressive symptoms in adolescents with and suicide-related outcomes (combined suicidal\nmoderate-to-severe depression. However, none ideation and suicide attempt) in adolescents treated\nof the antidepressants were significantly better with SSRIs.\nthan treatment as usual (TAU) in improving\n44\n3. Recommendations\nRemarks EML (13). There must be available and competent\ny The effects of antidepressants might vary between human resources to prescribe medicines safely and\nindividuals, so the adolescents, their carers and monitor any adverse effects.\nclinicians should carefully balance the risk–benefit\nImplementation considerations\nprofile of efficacy, acceptability and suicide risk in\ny Access to psychotherapy, particularly CBT, in line\nyoung people with depression on a case-by-case Certainty of evidence: low\njustification depressive symptoms and the positive effects of\ny evidence was extracted from two meta-analyses: antidepressants are considered to be small and not\nhetrick et al., 2021 (26 rcts) ..."
}